|
Genetic Test Predicts Obesity Risk in Early Childhood
|
Written by: J. Smith |
Hits: 262
|
|
Novo Nordisk Ends Partnership with Hims & Hers Over Safety Concerns
|
Written by: J. Smith |
Hits: 217
|
|
Lilly’s Once-Daily Oral GLP-1 Pill Shows Promise for Type 2 Diabetes
|
Written by: J. Smith |
Hits: 377
|
|
Dexcom Issues Updated Device Correction Notice for G6 and G7 Receivers Following FDA Recall
|
Written by: J. Smith |
Hits: 336
|
|
Lilly Adds High-Dose Zepbound to Self-Pay Program, Expands Access to All Approved Strengths
|
Written by: J. Smith |
Hits: 455
|
|
Insulet Launches Omnipod 5 iPhone App with Dexcom G7 Integration for All U.S. Users
|
Written by: J. Smith |
Hits: 227
|
|
Denmark Launches Ambitious Heart Disease Study with Record-Breaking Grant
|
Written by: J. Smith |
Hits: 277
|
|
Zepbound Outperforms Wegovy in Head-to-Head Obesity Trial
|
Written by: J. Smith |
Hits: 552
|
|
Large U.S. Study Finds No Increased Risk of Vision Loss from Semaglutide
|
Written by: J. Smith |
Hits: 430
|
|
CVS Shifts to Wegovy as Preferred Obesity Medication, Raising Questions About Access and Affordability
|
Written by: J. Smith |
Hits: 921
|
